Premium
Evaluation of 17 patients with COVID‐19 pneumonia treated with anakinra according to HScore, SOFA, MuLBSTA, and Brescia‐COVID respiratory severity scale (BCRSS) scoring systems
Author(s) -
Erden Abdulsamet,
Ozdemir Bahar,
Karakas Ozlem,
Mutlu Nevzat Mehmet,
Izdes Seval,
Kalem Ayse Kaya,
Bilir Yeşim Aybar,
Aypak Adalet,
Akinci Esragul,
Guner Rahmet,
Kucuksahin Orhan
Publication year - 2021
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.26473
Subject(s) - anakinra , medicine , pneumonia , sofa score , coinfection , severity of illness , covid-19 , tocilizumab , immunology , disease , intensive care unit , infectious disease (medical specialty) , virus
Abstract COVID‐19 pandemic has been affecting the whole world by increasing morbidity and mortality rates day by day. Treatment algorithms have been attempted as parallel to the increasing experience with COVID‐19. In the pathogenesis of this virus pro‐inflammatory cytokine storm has been called to have the main role. The right timing should be made for treatments. We proposed IL‐ 1 blocking by anakinra in seventeen COVID‐19 patients at high risk of worsening. Patients were assessed according to HScore, SOFA (Sequential Organ Failure Assessment Score = SOFA), MuLBSTA Score (multilobular infiltration, hypo‐lymphocytosis, bacterial coinfection, smoking history, hyper‐tension, and age), Brescia‐COVID respiratory severity scale (BCRSS). In our study, the mortality rate was 17.6%. Consequently, 1 (5.9%) patient was receiving low‐flow oxygen supply, 3 (17.6%) patients needed no longer oxygen supply and 10 (58.8%) patients were discharged from the hospital. According to the results of our study in the manner of general evaluation; we found that SOFA, MuLBSTA, and BCRSS scores were one step ahead according to HScore being insufficient to determine early phases of the disease. In our opinion, the prominent factors that emphasize the use of anakinra could be listed as comorbidity, risk, or presence of secondary infection, ongoing malignant disease. However, the other factors that enhance the use of anakinra in the situation of viremia also could be sorted as no response to full dose antivirals, antiviral side effects, or no success to antiviral treatment.